Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Chordoma × tazemetostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Follicular 4 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, B-Cell 3 Sarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Multiple Myeloma 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Chordoma 1

Interventions

tazemetostat 1 pembrolizumab 1 Zoledronic Acid 1 Pemetrexed 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05407441 2025-10-03

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Recruiting

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡